We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation.
- Authors
Sehhoon Park; Bo Mi Ku; Hyun Ae Jung; Jong-Mu Sun; Jin Seok Ahn; Se-Hoon Lee; Keunchil Park; Myung-Ju Ahn
- Abstract
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.
- Subjects
NON-small-cell lung carcinoma; EPIDERMAL growth factor receptors; PROTEIN-tyrosine kinases
- Publication
Cancer Research & Treatment, 2020, Vol 52, Issue 4, p1288
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2020.278